Ben Tre Pharmaceutical JSC (STC:DBT) Current Deferred Revenue: ₫0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:DBT Ben Tre Pharmaceutical JSC STC:DBT
13 GF Score
Price ₫12,500.00
! 1 Warning Sign
View Full Analysis

What is Ben Tre Pharmaceutical JSC Current Deferred Revenue?

Ben Tre Pharmaceutical JSC STC:DBT -0.79% 13 Current Deferred Revenue is ₫0.00 Mil as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Ben Tre Pharmaceutical JSC's current deferred revenue for the quarter that ended in . 20 was ₫0.00 Mil.

Ben Tre Pharmaceutical JSC Current Deferred Revenue Related Terms

Ben Tre Pharmaceutical JSC Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Ben Tre Pharmaceutical JSC's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ben Tre Pharmaceutical JSC Current Deferred Revenue Chart

Ben Tre Pharmaceutical JSC Annual Data
Trend
Current Deferred Revenue

Ben Tre Pharmaceutical JSC Semi-Annual Data
Current Deferred Revenue
STC:DBT
13GF Score
Ben Tre Pharmaceutical JSC STC:DBT
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₫0.00 Mil mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a Current Deferred Revenue of ₫0.00 Mil as of . 20. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ben Tre Pharmaceutical JSC and its competitors.
Is Ben Tre Pharmaceutical JSC's Current Deferred Revenue too high?
Ben Tre Pharmaceutical JSC's current Current Deferred Revenue is ₫0.00 Mil. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's Current Deferred Revenue compare to ZTS and UTHR?
Ben Tre Pharmaceutical JSC's Current Deferred Revenue of ₫0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ben Tre Pharmaceutical JSC and its competitors. Ben Tre Pharmaceutical JSC's current Current Deferred Revenue is ₫0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current Current Deferred Revenue of ₫0.00 Mil. The current Current Deferred Revenue is ₫0.00 Mil. Ben Tre Pharmaceutical JSC's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current Current Deferred Revenue is ₫0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ben Tre Pharmaceutical JSC Business Description

Address No. 6A3, National Highway 60, Phu Tan Ward, Vinh Long Province, Ben Tre, VNM
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
13GF Score

Get the complete analysis for STC:DBT

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫12,500.00
Price